Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) were up 6.7% during trading on Wednesday . The company traded as high as $19.11 and last traded at $19.35. Approximately 167,073 shares traded hands during mid-day trading, a decline of 90% from the average daily volume of 1,619,552 shares. The stock had previously closed at $18.13.
Analyst Ratings Changes
Several equities analysts have recently issued reports on the company. Evercore ISI boosted their price objective on Travere Therapeutics from $33.00 to $45.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 12th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Travere Therapeutics in a report on Friday, February 21st. Canaccord Genuity Group boosted their target price on shares of Travere Therapeutics from $22.00 to $45.00 and gave the company a "buy" rating in a research note on Wednesday, February 12th. JPMorgan Chase & Co. upped their price target on shares of Travere Therapeutics from $42.00 to $44.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. Finally, Citigroup increased their target price on shares of Travere Therapeutics from $31.00 to $35.00 and gave the stock a "buy" rating in a research report on Monday, February 24th. One analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to data from MarketBeat.com, Travere Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $30.62.
Get Our Latest Research Report on Travere Therapeutics
Travere Therapeutics Trading Up 3.1 %
The stock has a market cap of $1.75 billion, a P/E ratio of -4.81 and a beta of 0.75. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68. The business's 50 day simple moving average is $20.33 and its 200 day simple moving average is $17.77.
Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The company reported ($0.73) EPS for the quarter, missing analysts' consensus estimates of ($0.58) by ($0.15). Travere Therapeutics had a negative return on equity of 1,636.87% and a negative net margin of 137.90%. The business had revenue of $74.79 million for the quarter, compared to the consensus estimate of $72.38 million. On average, analysts expect that Travere Therapeutics, Inc. will post -1.4 earnings per share for the current fiscal year.
Insider Activity
In related news, SVP William E. Rote sold 2,437 shares of the business's stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $19.46, for a total value of $47,424.02. Following the sale, the senior vice president now directly owns 83,170 shares of the company's stock, valued at approximately $1,618,488.20. The trade was a 2.85 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CAO Sandra Calvin sold 54,244 shares of the business's stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $25.00, for a total transaction of $1,356,100.00. Following the sale, the chief accounting officer now directly owns 54,410 shares in the company, valued at $1,360,250. This trade represents a 49.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 206,335 shares of company stock worth $4,453,012. Insiders own 3.75% of the company's stock.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of TVTX. Driehaus Capital Management LLC lifted its stake in Travere Therapeutics by 608.1% in the 4th quarter. Driehaus Capital Management LLC now owns 2,217,975 shares of the company's stock valued at $38,637,000 after purchasing an additional 1,904,733 shares during the last quarter. BNP Paribas Financial Markets bought a new position in Travere Therapeutics in the 4th quarter valued at approximately $21,075,000. RA Capital Management L.P. bought a new position in Travere Therapeutics in the 4th quarter valued at approximately $20,033,000. Jennison Associates LLC bought a new position in shares of Travere Therapeutics during the fourth quarter valued at $14,222,000. Finally, Jacobs Levy Equity Management Inc. increased its position in shares of Travere Therapeutics by 36.7% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 2,174,213 shares of the company's stock worth $37,875,000 after buying an additional 583,836 shares during the period.
About Travere Therapeutics
(
Get Free Report)
Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Further Reading
Before you consider Travere Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Travere Therapeutics wasn't on the list.
While Travere Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.